Clinical Trials

70 enrolled

Phase 2 Not yet recruiting

Multiple Myeloma

NCT06948084 2026-03-18

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

80 enrolled

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT07463807 2026-03-18

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

162 enrolled

Phase 1 Active not recruiting

Multiple Myeloma

NCT03798678 2026-03-17

CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

36 enrolled

Multiple Myeloma

NCT04883242 2026-03-13

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

30 enrolled

Phase 1 Active not recruiting

Multiple Myeloma

NCT06203912 2026-03-05

Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma

3 enrolled

Multiple Myeloma

NCT04566328 2026-03-02

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Phase 3 Recruiting

1,450 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT04764942 2026-02-25

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

39 enrolled

Phase 1 Not yet recruiting

Multiple Myeloma

NCT07082270 2026-02-19

Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma

21 enrolled

Multiple Myeloma

NCT03031730 2026-02-10

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Phase 1 Terminated

35 enrolled 10 charts

Multiple Myeloma, Plasmacytoma

NCT07101445 2026-02-10

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

Phase 4 Recruiting

94 enrolled

Multiple Myeloma

NCT05497804 2026-02-03

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

17 enrolled

Multiple Myeloma

NCT05981209 2026-02-02

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies

Phase 1 Recruiting

27 enrolled

Multiple Myeloma

NCT06042725 2025-12-24

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

Phase 1 Recruiting

100 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT05392946 2025-10-29

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

49 enrolled

Multiple Myeloma

NCT03763162 2025-10-24

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

40 enrolled

Multiple Myeloma

NCT06785415 2025-09-30

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

Phase 1/2 Recruiting

37 enrolled

Phase 3 Active not recruiting

Multiple Myeloma

NCT01863550 2025-09-08

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

1,087 enrolled

Multiple Myeloma

NCT01415882 2025-09-05

Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib

165 enrolled 15 charts

Multiple Myeloma

NCT05208307 2025-09-02

Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

Phase 2 Recruiting

34 enrolled

Multiple Myeloma

NCT05288062 2025-08-20

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

17 enrolled 9 charts

Smoldering Multiple Myeloma, Multiple Myeloma

NCT04508790 2025-08-07

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Phase 2 Recruiting

29 enrolled

Multiple Myeloma

NCT01864018 2025-07-24

Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

Phase 1/2 Completed

87 enrolled 13 charts

Amyloidosis, Multiple Myeloma

NCT03713294 2025-06-24

Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma

37 enrolled 11 charts

Multiple Myeloma

NCT03012880 2025-06-04

Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma

80 enrolled 12 charts

Multiple Myeloma

NCT05561387 2025-06-04

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Phase 3 Recruiting

510 enrolled

Multiple Myeloma

NCT04892264 2025-05-18

Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

Phase 1 Terminated

5 enrolled

Multiple Myeloma

NCT02555839 2025-03-28

Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice

Completed

127 enrolled

Multiple Myeloma

NCT03457142 2025-03-04

Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy

15 enrolled 12 charts

Multiple Myeloma

NCT01903811 2024-12-20

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma

143 enrolled 14 charts

Multiple Myeloma, Recurrence

NCT03399539 2024-11-04

Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma

8 enrolled

Multiple Myeloma

NCT04756401 2024-09-26

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

52 enrolled

Multiple Myeloma

NCT02633059 2024-09-19

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Phase 1/2 Completed

33 enrolled 26 charts

Chromosome 17 deletion, Multiple Myeloma

NCT04352205 2024-07-01

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

17 enrolled

Multiple Myeloma, Renal Insufficiency

NCT05422027 2024-06-17

Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma

Phase 1/2 Recruiting

42 enrolled

Multiple Myeloma

NCT04956302 2024-06-06

Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

Phase 1 Terminated

1 enrolled

Multiple Myeloma

NCT02101944 2024-05-17

Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Classical hematologyPlasma cell

12 enrolled

Anemia, Multiple Myeloma

NCT04407442 2024-04-30

Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab

5 enrolled 12 charts

Multiple Myeloma

NCT03151811 2024-01-30

OCEAN

Phase 3 Terminated

495 enrolled 15 charts

Multiple Myeloma

NCT03506360 2024-01-09

Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

13 enrolled 11 charts

Multiple Myeloma

NCT02294357 2023-11-01

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

45 enrolled

Multiple Myeloma, Recurrence

NCT02547662 2023-10-30

Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia

Other hematologic neoplasmPlasma cell

17 enrolled 13 charts

Leukemia, Plasma Cell, Multiple Myeloma, Plasmacytoma

NCT03202628 2023-09-21

Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma

8 enrolled 14 charts

Multiple Myeloma

NCT02514382 2023-08-14

Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

14 enrolled

Phase 3 Active not recruiting

Multiple Myeloma

NCT03948035 2023-05-06

Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM

576 enrolled

Multiple Myeloma

NCT03841565 2022-06-15

Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Phase 2 Withdrawn

Multiple Myeloma

NCT02977494 2022-05-31

GMMG-DANTE

22 enrolled

Multiple Myeloma

NCT03256045 2022-05-09

Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

9 enrolled 12 charts

Multiple Myeloma

NCT01946152 2021-07-30

Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Terminated

21 enrolled 14 charts

Multiple Myeloma

NCT02569320 2021-06-15

HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma

9 enrolled